

Table of contents

Abstract	I
Zusammenfassung	III
Abbreviations	V
Table of contents	IX
1 Introduction	1
1.1 Diabetes mellitus	1
1.1.1 <i>Physiological glucose and lipid metabolism</i>	1
1.1.2 <i>Mechanisms of insulin signalling</i>	3
1.1.3 <i>Mechanisms of glucagon signalling</i>	5
1.1.4 <i>Glucose as a signalling effector</i>	7
1.1.5 <i>Types of diabetes</i>	8
1.1.6 <i>Pathogenesis of type 2 diabetes mellitus and associated complications</i>	8
1.1.7 <i>Diagnosis</i>	16
1.2 Pancreatic islets	17
1.2.1 <i>Pancreas architecture</i>	17
1.2.2 <i>In vitro pancreatic islet models</i>	18
1.3 Liver.....	20
1.3.1 <i>Liver architecture</i>	21
1.3.2 <i>In vitro liver models</i>	22
1.4 Current preclinical diabetes models.....	24
1.4.1 <i>Animal models</i>	24
1.4.2 <i>In vitro models</i>	27
1.4.3 <i>The drug development dilemma in the context of diabetes</i>	29
1.5 Microphysiological systems	30
1.5.1 <i>Single-organ systems</i>	30
1.5.2 <i>Multi-organ systems</i>	31
1.5.3 <i>Microphysiological systems for the study of diabetes</i>	34
1.6 Aim	37
2 Materials and methods	38
2.1 Materials	38

Table of contents

2.2	Cell culture.....	46
2.2.1	Cell sources	46
2.2.2	Cell counting and viability determination	46
2.2.3	Thawing of cryopreserved cells.....	47
2.2.4	Hepatic stellate cell and HepaRG monolayer culture.....	47
2.2.5	Passaging of hepatic stellate cells.....	48
2.2.6	Cryopreservation of hepatic stellate cells	48
2.2.7	Liver spheroid production	49
2.2.8	Liver spheroid collection.....	49
2.2.9	Pancreatic islet model handling and maintenance.....	50
2.2.10	Dynamic organ model cultivation in the multi-organ-chip	51
2.2.11	Glucose tolerance test	54
2.2.12	Glucose-stimulated insulin secretion (GSIS) assay.....	55
2.2.13	Akt phosphorylation.....	55
2.2.14	Glycogen storage assay.....	56
2.2.15	Gluconeogenesis assay.....	57
2.3	Metabolic analyses.....	57
2.3.1	Glucose concentration assays	58
2.3.2	Lactate assay	61
2.3.3	Lactate dehydrogenase assay	62
2.3.4	Insulin ELISA	63
2.3.5	Glucagon ELISA.....	64
2.3.6	Albumin ELISA.....	65
2.3.7	Protein content	66
2.3.8	Glycogen assay.....	67
2.4	Histology	68
2.4.1	Immunofluorescence staining of proteins.....	68
2.4.2	Apoptosis/proliferation visualization by TUNEL/Ki67	68
2.4.3	Nile Red staining of liver spheroid sections	69
2.4.4	Oil Red O staining of liver spheroids	69
2.5	Gene expression analysis.....	70
2.5.1	RNA isolation	70
2.5.2	cDNA synthesis.....	70
2.5.3	Real-time quantitative PCR.....	71
2.6	Statistical analysis.....	72

Table of contents

3	Results	74
3.1	Functional characterisation of suitable organ models.....	74
3.1.1	<i>Pancreatic islets</i>	74
3.1.2	<i>Liver spheroids</i>	77
3.2	Functional co-culture of pancreatic islet microtissues and liver spheroids	78
3.2.1	<i>Medium adaptation</i>	78
3.2.2	<i>Feasibility and long-term performance of the co-culture</i>	81
3.2.3	<i>Glucose tolerance test</i>	89
3.3	Robustness and reproducibility of the co-culture's performance	92
3.3.1	<i>Glucose tolerance test</i>	92
3.3.2	<i>Long-term pancreatic islet function</i>	96
3.3.3	<i>Long-term liver function</i>	97
3.4	Preventing medium-induced diabetes characteristics	100
3.4.1	<i>Glucose and hydrocortisone influence on pancreatic islet and liver function</i>	101
3.4.2	<i>Reduction of glucocorticoid and glucose concentrations in the co-culture</i>	105
4	Discussion	123
4.1	Did the organ models represent physiological organ functions?.....	123
4.2	Did the common co-culture medium support long-term viability and functionality of both organ models?.....	129
4.3	Was there a functional <i>in vivo</i> -like cross-talk between pancreatic islet microtissues and liver spheroids?.....	131
4.4	Were the organ models correctly scaled?	135
4.5	Did the common co-culture medium induce typical diabetes characteristics?	137
4.6	Was insulin resistance more pronounced in the second HepaRG batch?	140
4.7	Which ingredient of the common co-culture medium was causing typical diabetes characteristics?.....	143
4.8	Could a reduction of the glucocorticoid concentration prevent the development of typical diabetes characteristics?.....	147
5	Outlook and future directions	154
6	Appendix	156
	Supplementary figures.....	156

Table of contents

References	160
List of figures.....	182
List of Tables	184
Acknowledgments	186
Contribution to publications	188
Eidesstattliche Erklärung	190
Ausschluss weiterer Promotionsverfahren	190